Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Testing of cation carrier derivatives as prospective therapeutic agents for the treatment of B-cell-derived malignancies.

2019/35/B/NZ5/01445

Keywords:

CD20 cation carrier salinomycin rituximab

Descriptors:

  • NZ5_7: Human disease treatment
  • NZ6_1: Adaptive and innate immunity

Panel:

NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution :

Warszawski Uniwersytet Medyczny, Wydział Lekarski

woj.

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr Beata Pyrzyńska 

Number of co-investigators in the project: 7

Call: OPUS 18 - announced on 2019-09-16

Amount awarded: 2 345 246 PLN

Project start date (Y-m-d): 2020-07-06

Project end date (Y-m-d): 2024-07-05

Project duration:: 48 months (the same as in the proposal)

Project status: Project completed

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Articles in post-conference publications (3)
  1. Salinomycin-induced actin reorganization limits the presence of CD20 antigen on extracellular vesicles and augments the efficacy of lymphoma immunotherapy.
    Authors:
    Torun A., Zerrouqi A., Ciechanowicz A., Ng T., Czystowska-Kuzmicz M. and Pyrzynska B.
    Conference:
    Journal of Extracellular Vesicles (Volume 11, Issue S1); ISEV2022 Abstract Book (rok: 2022, tom: ISEV2022 Annual Meeting, strony: 165 (abstract PT07.07)), Wydawca: International Society for Extracellular Vesicles (ISEV)
    Data:
    konferencja 25-29 maja 2022
    Status:
    Published
    DOI:
    10.1002/jev2.12224 - link to the publication
  2. Salinomycin-induced actin reorganization limits the presence of CD20 antigen on extracellular vesicles and augments the efficacy of lymphoma immunotherapy.
    Authors:
    Torun A., Zerrouqi A., Ciechanowicz A., Ng T., Czystowska-Kuzmicz M. and Pyrzynska B.
    Conference:
    Journal of Extracellular Vesicles - ISEV2022 abstract book (rok: 2022, tom: ISEV2022 Annual Meeting, strony: ), Wydawca: ISEV
    Data:
    konferencja 25-29 maja 2022
    Status:
    Accepted for publication
  3. Salinomycin-induced actin reorganization limits the presence of CD20 antigen on extracellular vesicles and augments the efficacy of lymphoma immunotherapy.
    Authors:
    Torun A., Zerrouqi A., Ciechanowicz A., Ng T., Czystowska-Kuzmicz M. and Pyrzynska B.
    Conference:
    Journal of Extracellular Vesicles (Volume 11, Issue S1); ISEV2022 Abstract Book (rok: 2022, tom: ISEV2022 Annual Meeting, strony: 165 (abstract PT07.07)), Wydawca: International Society for Extracellular Vesicles (ISEV)
    Data:
    konferencja 25-29 maja 2022
    Status:
    Published
    DOI:
    10.1002/jev2.12224 - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy